Abstract
Even with transformative therapies, multiple myeloma is a relapsing and ultimately fatal disease. We previously reported that targeting an attenuated form of IFNα, or Attenukine™, to MM tumor cells via direct fusion to an anti-CD38 antibody (TAK-573) has direct anti-proliferative activity on MM cancer cells in vitro and induces robust and durable responses in MM xenograft tumor models. Here we demonstrate the anti-tumor impact of TAK-573, alone and in combination with SOC agents in MM xenograft tumor models in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.